Pharmaceuticals
- Home
- Therapeutic Solutions
- Pharmaceuticals
The unique capabilities of our BioCellicitation platform enable us create Health & Wellness products for both the Pharmaceutical and Nutraceutical verticals.
Developing products for the Pharmaceutical market is a future profit pillar for BioHarvest Sciences, as we target the application of our bio-active compositions in the form of Adjuncts and Active Pharmaceutical Ingredients (API’s)
Vinia - the adjunct for pharma that makes their active solutions more effective
The top 10 highest grossing drugs in the USA only have 4.1%-25% efficacy
With RGC’s ability to enhance arterial, venous, and capillary dilation significantly, we make pharmaceuticals more efficacious as actives can now reach the far corners of our extremities and organs, impacting significantly more cells.
with vinia
without
BIOHARVEST IS WORKING TO PARTNER WITH PHARMA TO DEVELOP RED GRAPE CELL POWDER AND OLIVE CELL POWDER INTO ACTIVE PHARMACEUTICAL INGREDIENTS (API)
Active pharmaceutical Ingredients (API) refer to the active ingredient contained in any drug. Any active ingredient is a substance that directly affects the ailment or targets the disease and is intended to use in manufacturing is known as API. These substances are considered crucial as they provide pharmacological activity or direct effects in the diagnosis, cure, treatment, prevention, or affect the body’s structure.
We are implementing Clinical Trial Pilot programs to prioritize indications
To best prioritize the development of our Red Grape Cells (RGC) and Olive Cell (Products) into FDA approved API’s, Bioharvest is currently implementing a number of clinical trial pilots to allow us to select the optimal indications to partner with Pharma in the Investigational New Drug (IND) Drug Development Process
BHSC targeting 4 key indications for its plant cell compositions where current pharma solutions can be optimized
Clinical Trial Initiatives & API
SKIN HEALTH
(Eczema/Atopic Dermatitis, Psoriasis)
Eczema/atopic derm. – 49.4 mil.
Psoriasis – 7.5 mil.
16.8% population
MULTIPLE SCLEROSIS RELATED OPTIC NEURITIS
Cases 1,000,000
with eye health issues 700,000
.3% population
Glioblastoma
annually 10,560
Orphan Drug
.003% population
NAFLD/
Fatty Liver
cases 90,000,000 mil.
26% population